i'm not so sure a r/s would be the death knell here. first off, its a possiblity of one, not definite. now, even if they did implement it down the road, lets plug in some parameters.... assume a 1 cent price at the time of a split and it goes 1/100. that bumps the price to a buck. still a price certainly manageable by most investors. however, it also retires a huge amount of shares in the company as well. with what we have in the pipeline, it still remains an attractive investment to anyone,including any pharma partner.
kid, you have been uncharacteristically silent here. i would relish and respect your thoughts on how this may pan out monday morning, and longer term. TIA
